clib with hydrocodone is necessary, as the systemic exposure of hydrocodone may be increased resulting in an increase in treatment-related adverse reactions including sedation and respiratory depression; adjust the dose of hydrocodone if necessary. Ribociclib is a moderate CYP3A4 inhibitor and hydrocodone is a CYP3A4 substrate.
Hydrocodone; Phenylephrine: (Moderate) Use caution if coadministration of ribociclib with hydrocodone is necessary, as the systemic exposure of hydrocodone may be increased resulting in an increase in treatment-related adverse reactions including sedation and respiratory depression; adjust the dose of hydrocodone if necessary. Ribociclib is a moderate CYP3A4 inhibitor and hydrocodone is a CYP3A4 substrate.
Hydrocodone; Potassium Guaiacolsulfonate: (Moderate) Use caution if coadministration of ribociclib with hydrocodone is necessary, as the systemic exposure of hydrocodone may be increased resulting in an increase in treatment-related adverse reactions including sedation and respiratory depression; adjust the dose of hydrocodone if necessary. Ribociclib is a moderate CYP3A4 inhibitor and hydrocodone is a CYP3A4 substrate.
Hydrocodone; Potassium Guaiacolsulfonate; Pseudoephedrine: (Moderate) Use caution if coadministration of ribociclib with hydrocodone is necessary, as the systemic exposure of hydrocodone may be increased resulting in an increase in treatment-related adverse reactions including sedation and respiratory depression; adjust the dose of hydrocodone if necessary. Ribociclib is a moderate CYP3A4 inhibitor and hydrocodone is a CYP3A4 substrate.
Hydrocodone; Pseudoephedrine: (Moderate) Use caution if coadministration of ribociclib with hydrocodone is necessary, as the systemic exposure of hydrocodone may be increased resulting in an increase in treatment-related adverse reactions including sedation and respiratory depression; adjust the dose of hydrocodone if necessary. Ribociclib is a moderate CYP3A4 inhibitor and hydrocodone is a CYP3A4 substrate.
Hydroxychloroquine: (Major) Avoid coadministration of ribociclib with hydroxychloroquine due to an increased risk for QT prolongation. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Hydroxychloroquine has also been associated with QT prolongation. Concomitant use may increase the risk for QT prolongation.
Hydroxyprogesterone: (Minor) Use caution if coadministration of ribociclib with hydroxyprogesterone is necessary, as the systemic exposure of hydroxyprogesterone may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and hydroxyprogesterone is a CYP3A4 substrate.
Hydroxyzine: (Major) Avoid coadministration of ribociclib with hydroxyzine due to an increased risk for QT prolongation and torsade de pointes (TdP). Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Postmarketing data indicate that hydroxyzine causes QT prolongation and TdP. Concomitant use may increase the risk for QT prolongation.
Ibrutinib: (Major) If coadministered with ribociclib, initiate ibrutinib therapy at a reduced dose of 140 mg/day PO for the treatment of B-cell malignancy or 420 mg/day PO for the treatment of chronic graft-versus-host disease; monitor patients more frequently for ibrutinib toxicity (e.g., hematologic toxicity, bleeding, infection). Ibrutinib is a CYP3A4 substrat |
